Dopamine transporter single photon emission computerized tomography in the diagnosis of dementia with Lewy bodies

Movement Disorders

Volumn 24, Issue SUPPL. 2, 2009, Pages

  Walker, Rodney W H ^a   Walker, Zuzana ^b  

^a BARTS HEALTH NHS TRUST   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Dementia; Lewy bodies; SPECT

Indexed keywords

3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; DOPAMINE; DOPAMINE TRANSPORTER; IODINE 123; NORTROPANE DERIVATIVE;

ARTICLE; AUTOPSY; DEMENTIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFUSE LEWY BODY DISEASE; DOPAMINERGIC NERVE CELL; HUMAN; MEDICAL ASSESSMENT; NERVE CELL DEGENERATION; NERVE ENDING; NIGRONEOSTRIATAL SYSTEM; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROBABILITY; PROTEIN BINDING; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

AUTOPSY; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; LEWY BODY DISEASE; NEOSTRIATUM; NEUROPSYCHOLOGICAL TESTS; SUBSTANTIA NIGRA; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 72849147465     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22591     Document Type: Article

References (30)

1. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003;60:387-392. (Pubitemid 36314364)
2. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008;23:837-844.
3. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-1124. (Pubitemid 26374873)
4. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863-1872. (Pubitemid 43970103)
5. Piggott MA, Marshall EF, Thomas N, et al. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's disease; rostro-caudal distribution. Brain 1999;122:1449-1468.
6. Suzuki M, Desmond TJ, Albin RL, Frey KA. Striatal monoaminergic terminals in Lewy body and Alzheimer's dementias. Ann Neurol 2002;51:767-771. (Pubitemid 34568857)
7. Hu XS, Okamura N, Arai H, et al. 18F-fluorodopa PET study of striatal dopamine uptake in the diagnosis of dementia with Lewy bodies. Neurology 2000;55:1575-1577.
8. Gilman S, Koeppe RA, Little R, et al. Striatal monoamine terminals in Lewy body dementia and Alzheimer's disease. Ann Neurol 2004;55:774-780. (Pubitemid 38702572)
9. Kuikka JT, Bergstrom KA, Ahonen A, et al. Comparison of iodine-123 labelled 2 beta-carbomethoxy-3 beta-(4-iodophenyl) tropane and 2 beta-carbomethoxy-3 beta-(4-iodophenyl)-N-(3-fluoropropyl) nortropane for imaging of the dopamine transporter in the living human brain. Eur J Nucl Med 1995;22:356-360.
10. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-2301.
11. Walker Z, Jaros E, Walker RW, et al. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry 2007;78:1176-1181. (Pubitemid 350057277)
12. McKeith I, O'Brien J, Walker Z, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 2007;6:305-313. (Pubitemid 46367938)
13. Walker Z, Costa DC, Walker RWH, et al. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 2002;73:134-140. (Pubitemid 41655939)
14. Donnemiller E, Heilmann J, Wenning GK, et al. Brain perfusion scintigraphy with 99mTc-HMPAO or 99mTc-ECD and 123I- beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease. Eur J Nucl Med 1997;24:320-325. (Pubitemid 27165863)
15. Ransmayr G, Seppi K, Donnemiller E, et al. Striatal dopamine transporter function in dementia with Lewy bodies and Parkinson's disease. Eur J Nucl Med 2001;28:1523-1528. (Pubitemid 32938402)
16. Ceravolo R, Volterrani D, Gambaccini G, et al. Dopaminergic degeneration and perfusional impairment in Lewy body dementia and Alzheimer's disease. Neurol Sci 2003;24:162-163. (Pubitemid 37304293)
17. Walker Z, Costa DC, Walker RW, et al. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison. Neurology 2004;62:1568-1572. (Pubitemid 38608197)
18. O'Brien JT, Colloby S, Fenwick J, et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 2004;61:919-925. (Pubitemid 38747333)
19. Ceravolo R, Volterrani D, Gambaccini G, et al. Presynaptic nigro-striatal function in a group of Alzheimer's disease patients with parkinsonism: evidence from a dopamine transporter imaging study. J Neural Transm 2004;111:1065-1073. (Pubitemid 39037127)
20. McKeith IG, Ballard CG, Perry RH, et al. Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology 2000;54:1050-1058. (Pubitemid 30151844)
21. McKeith I, Mintzer J, Aarsland D, et al. Dementia with Lewy bodies. Lancet Neurol 2004;3:19-28.
22. Burton EJ, Barber R, Mukaetova-Ladinska EB, et al. Medial temporal lobe atrophy on MRI differentiates Alzheimer's disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosis. Brain 2009;132(Pt 1):195-203.
23. Claassen DO, Parisi JE, Giannini C, Boeve BF, Dickson DW, Josephs KA. Frontotemporal dementia mimicking dementia with Lewy bodies. Cogn Behav Neurol 2008;21:157-163.
24. Sedaghat F, Gotzamani-Psarrakou A, Dedousi E, et al. Evaluation of dopaminergic function in frontotemporal dementia using I-FP-CIT single photon emission computed tomography. Neurodegener Dis 2007;4:382-385. (Pubitemid 47123464)
25. Klaffke S, Kuhn AA, Plotkin M, et al. Dopamine transporters, D2 receptors, and glucose metabolism in corticobasal degeneration. Mov Disord 2006;21:1724-1727.
26. O'Sullivan SS, Burn DJ, Holton JL, Lees AJ. Normal dopamine transporter single photon-emission CT scan in corticobasal degeneration. Mov Disord 2008;23:2424-2426.
27. Seppi K, Scherfler C, Donnemiller E, et al. Topography of dopamine transporter availability in progressive supranuclear palsy: a voxelwise [123I]beta-CIT SPECT analysis. Arch Neurol 2006;63:1154-1160. (Pubitemid 44232324)
28. Zaccai J, Brayne C, McKeith I, Matthews F, Ince PG. Patterns and stages of alpha-synucleinopathy: relevance in a population-based cohort. Neurology 2008;70:1042-1048.
29. Dickson DW, Fujishiro H, DelleDonne A, et al. Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Acta Neuropathol 2008;115:437-444.
30. O'Brien JT, McKeith IG, Walker Z, et al. Diagnostic accuracy of 123I-FP-CIT SPECT in possible dementia with Lewy bodies. Br J Psychiatry 2009;194:34-39.